Decision and Details
Board of DirectorsExecution of a special overdraft facility agreement
To secure a financing facility for the activities leading up to the application for manufacturing and marketing approval for HS-001 and the prompt establishment of a manufacturing and sales structure after approval. The facility will also increase available liquidity and enable the Company to pursue its business activities more flexibly and steadily.
No revision has been made to the earnings forecast for the fiscal year ending December 2026.
| Item | Details |
|---|---|
| Matter Covered | Execution of a special overdraft facility agreement |
| Decision-Making Body | Board of Directors |
| Decision Date | 14 August 2026 |
| Implementation Date | 14 August 2026 (agreement execution date; resolution approved) |
| Period Covered | 1 year |
| Amount | Contract amount: ¥2 billion |
| Impact on Business Performance | No revision has been made to the earnings forecast for the fiscal year ending December 2026. |
| Reason | To secure a financing facility for the activities leading up to the application for manufacturing and marketing approval for HS-001 and the prompt establishment of a manufacturing and sales structure after approval. The facility will also increase available liquidity and enable the Company to pursue its business activities more flexibly and steadily. |
| Future plans | The Company will proceed with consultations with the PMDA (Pharmaceuticals and Medical Devices Agency) and other activities, targeting the submission of an application for manufacturing and marketing approval during 2026. The Company will also prepare for the prompt establishment of a manufacturing and sales structure after approval. |
Items this document does not state (3)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To secure a financing facility for the activities leading up to the application for manufacturing and marketing approval for HS-001 and the prompt establishment of a manufacturing and sales structure after approval. The facility will also increase available liquidity and enable the Company to pursue its business activities more flexibly and steadily.